Autentificare
NeuroPsy InfoHubÎnțelege · Sprijin · ProgresCere sprijin

Informație de încredere. Sprijin real.

Ai întrebări despre autism, ADHD, anxietate sau depresie? Găsești ghiduri clare, verificate de specialiști. Acum, acces gratuit.

Începe gratuitSunt părinteSunt specialist
Spațiu publicitar disponibil — bannerul mare de susSpațiu publicitar disponibil — bannerul mare de sus

Explorează temele

Caută tot →

Sănătate mintală și neurodezvoltare

AutismSpectrul autist și particularitățile asociate.226 de articole
ADHDAtenție, impulsivitate și hiperactivitate.208 articole
Sindrom DownDezvoltare și sprijin pentru sindromul Down.59 de articole
AnxietateÎngrijorare excesivă, tensiune, atacuri de panică.75 de articole
DepresieTristețe persistentă, lipsa energiei și a motivației.110 articole
AdicțiiDependențe de substanțe și comportamentale.137 de articole

Afecțiuni neurologice

DemențeBoala Alzheimer și alte forme de demență.74 de articole
AVC și AITAccident vascular cerebral și recuperare, la orice vârstă.67 de articole
Leziuni medulareLeziuni medulare, paraplegie și tetraplegie.59 de articole
EpilepsieCrize epileptice și managementul lor.128 de articole
ParkinsonBoala Parkinson și tulburări de mișcare.65 de articole
Scleroză multiplăScleroza multiplă și viața cu aceasta.72 de articole
Traumatisme cranio-cerebraleTraumatisme cranio-cerebrale și recuperare.88 de articole

Articole și ghiduri recomandate

PublicToțiPentru oricineSpecialiști
VârstăToate vârsteleCopiiTineriAdulțiVârstnici
StudiuEpilepsieÎncredere bună20.06.2026

Adverse events of dual anti-seizure medication: Real-life data from a tertiary epilepsy clinic

A retrospective study of 595 epilepsy patients on dual anti-seizure medications identified common adverse events including sleepiness (62%), concentration difficulties (55%), and memory problems (53%). Female sex, certain drug combinations (levetiracetam/valproic acid, lamotrigine/valproic acid), drug resistance, and focal/unclassified epilepsy were independently associated with higher adverse event burden.

StudiuEpilepsieÎncredere înaltă20.06.2026

Drug-Resistant Frontal Lobe Epilepsy: A Review of Epidemiology, Diagnosis, and Surgical Management

This review addresses the clinical challenge of drug-resistant frontal lobe epilepsy, the second most common epilepsy type, which is complicated by the frontal lobe's large size making seizure focus localization difficult. The article examines epidemiology, etiologic factors (particularly cortical developmental abnormalities), symptomatology, and advances in neurophysiological and neuroimaging techniques including magnetoencephalography, quantitative PET, 7T MRI, and artificial intelligence-assisted morphometric analysis to improve lesion detection and surgical outcomes.

StudiuEpilepsieÎncredere înaltă20.06.2026

The impact of the new definition of epilepsy on diagnosis, treatment, and short-term outcomes—A prospective study

A prospective study of 235 adult patients with first seizures examined how the 2014 ILAE definition of epilepsy (allowing earlier diagnosis) affected clinical outcomes compared to previous criteria. Among 146 patients diagnosed with epilepsy using new criteria, 72% remained seizure-free at 12-month follow-up, and anti-seizure medication significantly reduced seizure recurrence risk.

StudiuEpilepsieÎncredere bună20.06.2026

Pharmacogenetics of Anti-Seizure Medications in Arab Countries: A Comprehensive Review

This review examines how genetic variations in Arab populations influence the efficacy, safety, and individual responses to anti-seizure medications, identifying specific genetic markers that can predict drug resistance and optimize dosing. Genetic testing for variants in genes such as MTHFR, MDR1, ABCB1, and others enables personalized treatment approaches to improve seizure control and minimize adverse drug reactions.

StudiuEpilepsieÎncredere bună20.06.2026

UGT Polymorphisms and Seizure Control in Pregnant Women Treated with Lamotrigine

This study examined whether genetic variations in UGT enzymes (which metabolize the antiepileptic drug lamotrigine) affect seizure control in 47 pregnancies of women with epilepsy. While UGT genotype did not directly predict seizure outcomes, recent pre-pregnancy seizure history (within 6-12 months) was a significant predictor of seizure recurrence during pregnancy and postpartum.